✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
BGB-3111 is an investigational drug.
There have been 123 clinical trials for BGB-3111. The most recent clinical trial was a Phase 2 trial, which was initiated on January 25th 2017.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Carcinoma. The leading clinical trial sponsors are BeiGene, National Cancer Institute (NCI), and BeiGene USA, Inc.
There are nine US patents protecting this investigational drug and eighty-three international patents.
Recent Clinical Trials for BGB-3111
|Mirdametinib + BGB-3245 in Advanced Solid Tumors||SpringWorks Therapeutics, Inc.||Phase 1/Phase 2|
|Safety, Pharmacokinetics and Antitumor Activity of BGB-B167alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants||BeiGene||Phase 1|
|A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.||BeiGene||Phase 1/Phase 2|
Top disease conditions for BGB-3111
Top clinical trial sponsors for BGB-3111
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|BGB-3111||See Plans and Pricing||Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators||BEIGENE, LTD. (Grand Cayman, KY)||See Plans and Pricing|
|BGB-3111||See Plans and Pricing||Treatment of pemphigus||PRINCIPIA BIOPHARMA INC. (South San Francisco, CA)||See Plans and Pricing|
|BGB-3111||See Plans and Pricing||Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators||BEIGENE SWITZERLAND GMBH (Basel, CH)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|BGB-3111||Australia||AU2014256633||2033-04-25||See Plans and Pricing|
|BGB-3111||Brazil||BR112015025260||2033-04-25||See Plans and Pricing|
|BGB-3111||Canada||CA2902686||2033-04-25||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|